Our People

Chris Denison

Partner,
European Patent Attorney

Bristol, London

Chris does life sciences patent work and is renowned for his expertise in the pharmaceutical sector. He handled the prosecution and opposition defence for most of the European patent portfolio and provided litigation support for two of the top-ten bestselling biopharmaceuticals. Chris also has an interest in the biotechnology, food & beverage, Medtech and oil & gas sectors.

His experience includes:

biologics especially antibody-based therapeutics

angiogenic molecules and anti-angiogenic therapies

gene manipulation

microbiology

functional/health foods and nutraceuticals

regenerative medicine including tissue engineering scaffolds

induction and control of stem cell differentiation

plant protection agents

microbially enhanced oil recovery.

Chris was “recommended” for patent prosecution in “IAM Patent 1000: The World’s Leading Patent Practitioners” 2012 -2015. IAM 2014 said “For companies with blockbuster biopharmaceuticals, there is nobody better than Chris Denison”. IAM 2015 says “Based in Bristol, life sciences virtuoso Christopher Denison has won a loyal following of multinational pharmaceutical companies, US universities, research institutes and a raft of foreign businesses. Chris is also recognised in the IAM Patent 1000, 2017. He is said to ‘blaze trail in biologics’.

In the 2018 edition of IAM Patent 1000, Chris is named a ‘life sciences savant‘ by researchers.

Chris contributed to a report prepared for the Japan Patent Office by the Japanese Institute of Intellectual Property into the patentability of functional foods, which influenced the recent change of JPO practice in this area. An English summary of the report is available here. (Source: Japanese Insutitute of Intellectual Property (IIP)).

His practice is focussed strongly on representation at the European Patent Office for overseas clients, including multinational pharmaceutical companies, US biotech companies of all sizes, US universities, Japanese multinationals, food companies, small biotech companies, universities and research institutes.

Chris has particular experience of large portfolio management, both of diverse portfolios arising from large research programmes and portfolios centred about particular products.

Chris has a degree in neuroscience from University of Cambridge.

Chris joined Mewburn Ellis LLP in 1996, qualifying as a Chartered Patent Attorney in 1999 and a European Patent Attorney in 2000. He joined the partnership in 2002.